Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

This study is testing whether adoptive T lymphocyte (immune cell) infusions — specifically norovirus-specific T cells (NST) — can treat chronic norovirus infection in immunocompromised patients. Norovirus is a common stomach bug that causes vomiting and diarrhea; in healthy people it resolves quickly, but in people with weakened immune systems (such as after a stem cell transplant or organ transplant), it can become a chronic, debilitating infection. This therapy infuses specially selected immune cells that specifically target norovirus. You may be eligible if: - You are between 3 months and 80 years old - You are immunocompromised due to a prior stem cell transplant, a primary immune deficiency, or a solid organ transplant - You have chronic norovirus infection, confirmed by two or more positive stool tests spanning at least 3 months, with ongoing symptoms - You have adequate blood counts and organ function - If you are on steroids for GVHD or other reasons, you are on a dose of less than 0.5 mg/kg/day of prednisone or equivalent You may NOT be eligible if: - You have received certain immune-suppressing antibody therapies (e.g., ATG, alemtuzumab, tocilizumab) within 28 days of the infusion - You have another uncontrolled active infection besides norovirus - You have other active gastrointestinal infections that could explain your symptoms - You have active GVHD of grades 2–4 or active relapse of a malignancy - You have received a small bowel transplant Talk to your transplant or immunology team about whether your norovirus infection has been formally confirmed with serial stool tests and whether your immune status is appropriate for this cell therapy.